Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;30(9):7355-7363.
doi: 10.1007/s00520-022-07118-y. Epub 2022 May 24.

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer

Mary Hwang  1 , Sarah Medley  2 , Faisal Shakeel  1 , Brett Vanderwerff  3 , Matthew Zawistowski  3 , Kelley M Kidwell  2 , Daniel L Hertz  4
Affiliations

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer

Mary Hwang et al. Support Care Cancer. 2022 Sep.

Abstract

Purpose: Cyclophosphamide is a commonly used cancer agent that is metabolically activated by polymorphic enzymes. This study aims to investigate the association between predicted activity of candidate pharmacogenes with severe toxicity during cyclophosphamide treatment.

Methods: Genome-wide genetic data was collected from an institutional genetic data repository for CYP2B6, CYP3A4, CYP2C9, CYP2C19, GSTA1, GSTP1, ALDH1A1, ALDH3A1, ABCC1, ABCB1, and ERCC1. Treatment and toxicity data were retrospectively collected from the patient's medical record. The a priori selected primary hypothesis was that patients who have CYP2B6 reduced metabolizer activity (poor or intermediate (PM/IM) vs. normal (NM) metabolizer) have lower risk of severe toxicity or cyclophosphamide treatment modification due to toxicity.

Results: In the primary analysis of 510 cyclophosphamide-treated patients with available genetic data, there was no difference in the odds of severe toxicity or treatment modification due to toxicity in CYP2B6 PM/IM vs. NM (odds ratio = 0.97, 95% Confidence Interval: 0.62-1.50, p = 0.88). In an exploratory, statistically uncorrected secondary analysis, carriers of the ALDH1A1 rs8187996 variant had a lower risk of the primary toxicity endpoint compared with wild-type homozygous patients (odds ratio = 0.31, 95% Confidence Interval: 0.09-0.78, p = 0.028). None of the other tested phenotypes or genotypes was associated with the primary or secondary endpoints in unadjusted analysis (all p > 0.05).

Conclusion: The finding that patients who carry ALDH1A1 rs8187996 may have a lower risk of cyclophosphamide toxicity than wild-type patients contradicts a prior finding for this variant and should be viewed with skepticism. We found weak evidence that any of these candidate pharmacogenetic predictors of cyclophosphamide toxicity may be useful to personalize cyclophosphamide dosing to optimize therapeutic outcomes in patients with cancer.

Keywords: ALDH1A1; CYP2B6; Cyclophosphamide; Pharmacogenetic; Toxicity; Treatment discontinuation.

PubMed Disclaimer

References

    1. Dirven HA, van Ommen B, van Bladeren PJ (1994) Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54(23):6215–6220 - PubMed
    1. Sládek NE (1999) Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 5(8):607–625 - PubMed
    1. Begg EJ, Helsby NA, Jensen BP (2012) Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. Pharmacogenomics 13(1):83–89. https://doi.org/10.2217/pgs.11.134;10.2217/pgs.11.134 - DOI - PubMed
    1. Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y et al (2015) Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet 30(2):149–153. https://doi.org/10.1016/j.dmpk.2014.09.009 - DOI - PubMed
    1. Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ et al (2010) The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 70(6):844–853. https://doi.org/10.1111/j.365-2125.010.03789.x - DOI - PubMed - PMC

LinkOut - more resources